Effects of Bezafibrate on Lipid and glucose metabolism in dyslipidemic patients with impaired glucose tolerance - Comparative analysis of the characteristics of dyslipidemia improving drugs for postprandial metabolic disorder.-

INTERVENTION: Participants in the bezafibrate treatment group will be received 400mg/day of bezafibrate during 3 months. If a patient's consent is obtained, the treatmentwill be continued for more 3 months. Participants in the atrovastatin treatment group will be received 10mg/day of atrovastatin during 3months. If a patient's consent is obtained, the treatment will be continued vfor more 3 months. CONDITION: Patients with metabolic syndrome PRIMARY OUTCOME: 1) Levels of triglycerides, HDL‐cholesterol, total cholesterol and LDL‐cholesterol; 2) Diameter of lipoproteins measured by HPLC ; 3)HbA1c (NGSP) and 75g OGTT (glucose and insulin levels at 0, 30, 60 and 120 min after glucose load); 4)Safety (Adverse effects including hypoglycemia, body weigh gain) SECONDARY OUTCOME: 1)MDA‐LDL levels and MDA‐LDL/LDL cholesterol; 2)Insulin sensitivity (HOMA‐IR, QUICKI); 3)Plasma adiponectin levels; 4)Plasma high sensitive C reactive protein levels; 5)Body weight, body mass index (BMI) and blood pressure; 6)Renal function and liver function tests INCLUSION CRITERIA: 1) Patients who have metabolic syndrome according to IDF definition without history of coronary heart disease. 2) Patients who have triglyceride levels of 150mg/dL or higher and have LDL cholesterol levels of 120mg/dL or higher after an overnight fasting. 3) Patients who give informed consent.